{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:29:44Z","timestamp":1786346984846,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13300-026-01888-y","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:17:13Z","timestamp":1781522233000},"page":"1119-1133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response"],"prefix":"10.1007","volume":"17","author":[{"given":"Muhammad Hamid Siddique","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholood Abdulla Hasan Abdulla","family":"Janahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afnan","family":"Tayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathima Musfira Mohamad","family":"Musaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Al Sheykh Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Hisham","family":"Al Toubah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Moen Abdul","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam","family":"Almarzooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardeen Mohammad","family":"Sayfoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad Abdulla Hasan Abdulla","family":"Janahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9551-1662","authenticated-orcid":false,"given":"Sobia","family":"Siddiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"10440","key":"1888_CR1","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"Collaborators GBDCoD","year":"2024","unstructured":"Collaborators GBDCoD. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)00367-2.","journal-title":"Lancet"},{"issue":"1","key":"1888_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/02763869.2019.1693231","volume":"39","author":"E Vardell","year":"2020","unstructured":"Vardell E. Global Health Observatory Data Repository. Med Ref Serv Q. 2020;39(1):67\u201374. https:\/\/doi.org\/10.1080\/02763869.2019.1693231.","journal-title":"Med Ref Serv Q"},{"key":"1888_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8074837","volume":"2022","author":"H Okati-Aliabad","year":"2022","unstructured":"Okati-Aliabad H, Ansari-Moghaddam A, Kargar S, Jabbari N. Prevalence of obesity and overweight among adults in the Middle East countries from 2000 to 2020: a systematic review and meta-analysis. J Obes. 2022;2022:8074837. https:\/\/doi.org\/10.1155\/2022\/8074837.","journal-title":"J Obes"},{"issue":"1","key":"1888_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-025-01959-4","volume":"25","author":"A Moradkhani","year":"2025","unstructured":"Moradkhani A, Azami M, Mohammadzadeh P, Baradaran HR, Saed L, Asvad K, et al. The prevalence of all types of diabetes and pre\u2011diabetes in the Eastern Mediterranean countries: a meta\u2011analysis study. BMC Endocr Disord. 2025;25(1):149. https:\/\/doi.org\/10.1186\/s12902-025-01959-4.","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"1888_CR5","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1111\/dom.16389","volume":"27","author":"E Abdelgadir","year":"2025","unstructured":"Abdelgadir E, Rashid F, Bashier A, Zidan M, McGowan B, Alawadi F. Prevalence of overweight and obesity in adults from the Middle East: a large-scale population-based study. Diabetes Obes Metab. 2025;27(7):3676\u201385. https:\/\/doi.org\/10.1111\/dom.16389.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1888_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/MED.0b013e3283444b09","volume":"18","author":"G Boden","year":"2011","unstructured":"Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):139\u201343. https:\/\/doi.org\/10.1097\/MED.0b013e3283444b09.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"1888_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"GBDO Collaborators","year":"2017","unstructured":"Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1614362.","journal-title":"N Engl J Med"},{"issue":"18","key":"1888_CR8","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2174\/1381612825666190708192134","volume":"25","author":"N Katsiki","year":"2019","unstructured":"Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Obesity, metabolic syndrome and the risk of microvascular complications in patients with diabetes mellitus. Curr Pharm Des. 2019;25(18):2051\u20139. https:\/\/doi.org\/10.2174\/1381612825666190708192134.","journal-title":"Curr Pharm Des"},{"issue":"11","key":"1888_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"ARG Look","year":"2016","unstructured":"Look ARG, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913\u201321. https:\/\/doi.org\/10.1016\/S2213-8587(16)30162-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1888_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","volume":"7","author":"Q Gong","year":"2019","unstructured":"Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452\u201361. https:\/\/doi.org\/10.1016\/S2213-8587(19)30093-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1888_CR11","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034.","journal-title":"Diabetes Care"},{"issue":"1","key":"1888_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijcard.2014.02.026","volume":"173","author":"CS Kwok","year":"2014","unstructured":"Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol. 2014;173(1):20\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2014.02.026.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1888_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dme.14215","volume":"37","author":"BJ Ammori","year":"2020","unstructured":"Ammori BJ, Skarulis MC, Soran H, Syed AA, Eledrisi M, Malik RA. Medical and surgical management of obesity and diabetes: what\u2019s new? Diabet Med. 2020;37(2):203\u201310. https:\/\/doi.org\/10.1111\/dme.14215.","journal-title":"Diabet Med"},{"issue":"10166","key":"1888_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X.","journal-title":"Lancet"},{"issue":"10","key":"1888_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"1888_CR16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"19","key":"1888_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"10","key":"1888_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1888_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"issue":"2","key":"1888_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"20","key":"1888_CR21","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"issue":"4","key":"1888_CR22","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1007\/s12325-022-02053-0","volume":"39","author":"AA Al Hayek","year":"2022","unstructured":"Al Hayek AA, Al Dawish MA. Evaluation of patient-reported satisfaction and clinical efficacy of once-weekly semaglutide in patients with type 2 diabetes: an ambispective study. Adv Ther. 2022;39(4):1582\u201395. https:\/\/doi.org\/10.1007\/s12325-022-02053-0.","journal-title":"Adv Ther"},{"issue":"9","key":"1888_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.4239\/wjd.v12.i9.1401","volume":"12","author":"IM El-Kebbi","year":"2021","unstructured":"El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: challenges and call for action. World J Diabetes. 2021;12(9):1401\u201325. https:\/\/doi.org\/10.4239\/wjd.v12.i9.1401.","journal-title":"World J Diabetes"},{"issue":"2","key":"1888_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/17512433.2023.2174099","volume":"16","author":"Z Ruan","year":"2023","unstructured":"Ruan Z, Jiang Y, Shi H, Jia R, Ung COL, Hu H. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. Expert Rev Clin Pharmacol. 2023;16(2):161\u201376. https:\/\/doi.org\/10.1080\/17512433.2023.2174099.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1888_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002619","author":"JF Yale","year":"2022","unstructured":"Yale JF, Bodholdt U, Catarig AM, Catrina S, Clark A, Ekberg NR, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care. 2022. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002619.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1888_CR26","unstructured":"UAE Ministry of Health and Prevention. UAE National Health Survey Report 2017\u20132018. 2019. https:\/\/cdn.who.int\/media\/docs\/default-source\/ncds\/ncd-surveillance\/data-reporting\/united-arab-emirates\/uae-national-health-survey-report-2017-2018.pdf?sfvrsn=86b8b1d9_1&download=true. Accessed 8 May 2026."},{"issue":"4","key":"1888_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbol JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1888_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","volume":"9","author":"JP Frias","year":"2021","unstructured":"Frias JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563\u201374. https:\/\/doi.org\/10.1016\/S2213-8587(21)00174-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1888_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102915","volume":"78","author":"BE Wilson","year":"2024","unstructured":"Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine. 2024;78:102915. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102915.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1888_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201337. https:\/\/doi.org\/10.1016\/j.diabres.2015.07.015.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"1888_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2(7):775\u201381. https:\/\/doi.org\/10.1001\/jamacardio.2017.1421.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1888_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5603\/cd.106464","volume":"14","author":"F Ahmed","year":"2025","unstructured":"Ahmed F, Merghani T, Altair Y, Qashlan A, Parsad H, Hamad F, et al. Glycemic and weight outcomes with semaglutide in Middle Eastern patients with type 2 diabetes. Clin Diabetol. 2025;14(6):309\u201314. https:\/\/doi.org\/10.5603\/cd.106464.","journal-title":"Clin Diabetol"},{"key":"1888_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61081393","author":"SJ Alarfaj","year":"2025","unstructured":"Alarfaj SJ. The effectiveness of semaglutide on a composite endpoint of glycemic control and weight reduction and its effect on lipid profile among obese type 2 diabetes patients. Medicina (Kaunas). 2025. https:\/\/doi.org\/10.3390\/medicina61081393.","journal-title":"Medicina (Kaunas)"},{"issue":"11","key":"1888_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"10516","key":"1888_CR35","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(25)01375-3.","journal-title":"Lancet"},{"issue":"9","key":"1888_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01888-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:00:43Z","timestamp":1786345243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01888-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01888-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sobia Siddiq received an unrestricted research grant from Novo Nordisk-UAE, who had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. Muhammad Hamid Siddique Mian, Kholood Abdulla Hasan Abdulla Janahi, Afnan Tayeb, Fathima Musfira Mohamad Musaffar, Nur Al Sheykh Khalil, Sarah Hisham Al Toubah, Abdul Moen Abdul Karim, Ahlam Almarzooqi, Fardeen Mohammad Sayfoo, Ahmed Hamadeh, and Mohannad Abdulla Hasan Abdulla Janahi have nothing to disclose.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Emirates Health Services Research Ethics Committee approved the protocol (REC number: MOHAP\/DXB-REC\/D.D.A\/No.208\/2024). Written informed consent for the use of de-identified clinical data was obtained where required by institutional policy.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}